港股異動 | 三生製藥(1530.HK)漲超8%創逾5個月新高 暫三日連升累漲超18%
格隆匯7月6日丨三生製藥(1530.HK)今日續漲,暫三日連升累漲超18%,盤中高見11.68港元創今年1月24日以來逾5個月新高。現報11.66港元,漲8.36%,暫成交2.7億港元,最新總市值296億港元。里昂近日發研報指,三生製藥注射用伊尼妥單抗(賽普汀)經過多年研發及申請後,日前終於得到國家藥品監督管理局批准,成為首款用於治療轉移性乳腺癌的國產抗HER2藥物,有望打破進口產品壟斷市場的局面,並在未來數年為公司提供增長動力。該行維持其“跑贏大市”評級,升目標價至11.87港元。格隆匯平台7月2日發佈深度分析文章《三生製藥(1530.HK):創新研發開花結果,商業化加速,估值有望提升》,詳情可點擊下列鏈接瞭解。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.